What implications does the 10-day RSI indicator have for CNCR?

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CNCR's RSI Indicator exited the oversold zone, 25 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

What does a 3-day price advance indicate for CNCR?

Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNCR advanced for three days, in 243 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

CNCR

AS OF

Apr 3, 01:00 PM (EDT)

Price

$8.96

Change

-$0.41 (-4.37%)

Net Assets

7.05M

OUR PRODUCTS

MOBILE APPS

GENERAL INFO

Help

+Compare

CNCR

ETF ticker: NASDAQ

AS OF

Apr 3, 01:00 PM (EDT)

Price

$8.96

Change

-$0.41 (-4.37%)

Net Assets

7.05M

CNCR stock forecast, quote, news & analysis

The investment seeks to track the performance, before fees and expenses, of the Range Oncology Therapeutics Index... Show more

Category: #Health

Get AI intraday signals

CNCR

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For CNCR
(Try 14 days for Free)

A.I.Advisor

published price charts

View to see Real Time Patterns for CNCR (Try 14 days for Free)

Ad is loading...

A.I.Advisor

a Summary for CNCR with price predictions

Mar 13, 2025

CNCR in -5.22% downward trend, sliding for three consecutive days on March 04, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CNCR declined for three days, in of 313 cases, the price declined further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CNCR's RSI Indicator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNCR advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor

published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to track the performance, before fees and expenses, of the Range Oncology Therapeutics Index. The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.

Market Cap

The average market capitalization across the Range Cancer Therapeutics ETF ETF is 8.5B. The market cap for tickers in the group ranges from 8.82M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is APLM at 8.82M.

High and low price notable news

The average weekly price growth across all stocks in the Range Cancer Therapeutics ETF ETF was 9%. For the same ETF, the average monthly price growth was 91%, and the average quarterly price growth was 54%. PRLD experienced the highest price growth at 23%, while ACRV experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Range Cancer Therapeutics ETF ETF was 2%. For the same stocks of the ETF, the average monthly volume growth was -23% and the average quarterly volume growth was 75%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50

P/E Growth Rating: 80

Price Growth Rating: 81

SMR Rating: 92

Profit Risk Rating: 93

Seasonality Score: 2 (-100 ... +100)

View a ticker or compare two or three

Compare

CNCR

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For CNCR
(Try 14 days for Free)

Ad is loading...

A.I. Advisor

published General Information

General Information

Category Health

Profile

Fundamentals

Details